S-1 for treatment of advanced hepatocellular carcinoma: a systematic review of the literature

Wu-Kui Huang; Li-na You; Shu-Fa Yang; Deng-Yao Liu; Mo Liu; Xi-Wen Fan

doi:10.5114/wo.2017.66653

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2017
vol. 21

Send email

Copy url:

abstract:

Review paper

S-1 for treatment of advanced hepatocellular carcinoma: a systematic review of the literature

Wu-Kui Huang

,

Li-na You

,

Shu-Fa Yang

,

Deng-Yao Liu

,

Mo Liu

,

Xi-Wen Fan

Contemp Oncol (Pozn) 2017; 21 (1): 16-20

DOI: https://doi.org/10.5114/wo.2017.66653

Online publish date: 2017/03/22

View full text Get citation

PlumX metrics:

Hepatocellular carcinoma (HCC) is the most common liver neoplasm worldwide. Based on its potent inhibition of dihydropyrimidine dehydrogenase (DPD), S-1 is expected to be more active than other fluoropyrimidines against HCC with DPD activity. This systematic review was aimed to assess the efficacy and safety of S-1 for treatment of advanced HCC.

PubMed, the Cochrane Library, EMBA-

SE, and ClinicalTrials.gov were searched using the terms “Hepatocellular Carcinoma” or “HCC” or “Hepatoma” or “Liver cancer” and ‘‘S-1’’. Outcomes of main interest included overall survival (OS) and toxicities.

We identified four studies of S-1 treatment alone from 1059 references, including a total of 272 patients. There were two original articles and two conference abstracts. The percentage of male patients ranged from 88 to 91.3% and median age ranged from 59 to 70 years. Median OS ranged from 8.6 to 16.5 months. The incidences of toxicity of more than 50% were thrombocytopaenia and fatigue. According to the original description, toxicities were acceptable.

The current evidence from the available clinical studies suggests that S-1 may be an effective and tolerable treatment for advanced HCC. Further clinical studies are warranted to further investigate this treatment option.

keywords:

S-1 for treatment of advanced hepatocellular carcinoma: a systematic review of the literature

Wu-Kui Huang , Li-na You , Shu-Fa Yang , Deng-Yao Liu , Mo Liu , Xi-Wen Fan

hepatocellular carcinoma, S-1, systematic review

Wu-Kui Huang

,

Li-na You

,

Shu-Fa Yang

,

Deng-Yao Liu

,

Mo Liu

,

Xi-Wen Fan